The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
The availability and affordability of selected essential medicines for chronicl diseases in six low- and middle-income countries
Open accessAbstract
Objective To assess the availability and affordability of medicines used to treat cardiovascular disease, diabetes, chronic respiratory disease and glaucoma and to provide palliative cancer care in six low-and middle-income countries.Methods A survey of the availability and price of 32 medicines was conducted in a representative sample of public and private medicine outlets in four geographically defined areas in Bangladesh, Brazil, Malawi, Nepal, Pakistan and Sri Lanka.We analysed the percentage of these medicines available, the median price versus the international reference price (expressed as the median price ratio) and affordability in terms of the number of days' wages it would cost the lowest-paid government worker to purchase one month of treatment.Findings In all countries < 7.5% of these 32 medicines were available in the public sector, except in Brazil, where 30% were available, and Sri Lanka, where 28% were available.Median price ratios varied substantially, from 0.09 for losartan in Sri Lanka to 30.44 for aspirin in Brazil.In the private sector in Malawi and Sri Lanka, the cost of innovator products (the pharmaceutical product first given marketing authorization) was three times more than generic medicines.One month of combination treatment for coronary heart disease cost 18.4 days' wages in Malawi, 6.1 days' wages in Nepal, 5.4 in Pakistan and 5.1 in Brazil; in Bangladesh the cost was 1.6 days' wages and in Sri Lanka it was 1.5.The cost of one month of combination treatment for asthma ranged from 1.3 days' wages in Bangladesh to 9.2 days' wages in Malawi.The cost of a one-month course of intermediate-acting insulin ranged from 2.8 days' wages in Brazil to 19.6 in Malawi.Conclusion Context-specific policies are required to improve access to essential medicines.Generic products should be promoted by educating professionals and consumers, by implementing appropriate policies and incentives, and by introducing market competition and/or price regulation.Improving governance and management efficiency, and assessing local supply options, may improve availability.Prices could be reduced by improving purchasing efficiency, eliminating taxes and regulating mark-ups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Metformin monotherapy for type 2 diabetes mellitus
Saenz, A., Fernandez-Esteban, I., Mataix, A., Ausejo Segura, M., Roqué i Figuls, M., & Moher, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002966.pub3 · Cited by 308
Retracted(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
(2003) · Journal of Hypertension · doi:10.1097/00004872-200311000-00002 · Cited by 2,672
Preventing chronic diseases: a vital investment
Vita-Finzi, L., & Who, G. E. (2005) · Cited by 1,679
World Development Indicators 2004
Bank, W. (2004) · World Bank, Washington, DC eBooks · doi:10.1596/0-8213-5729-8 · Cited by 679
&NA; (1994) · Survey of Anesthesiology · doi:10.1097/00132586-199406000-00052 · Cited by 487
The cost of diabetes in Latin America and the Caribbean.
Barceló, A., Aedo, C., Rajpathak, S. N., & Robles, S. C. (2003) · Europe PMC (PubMed Central) · Cited by 377
WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE).
Mendis, S., Abegunde, D., Yusuf, S., Ebrahim, S. B. J., Shaper, G., Ghannem, H., & Shengelia, B. (2005) · Europe PMC (PubMed Central) · Cited by 289
Self-citationWorld Development Indicators 2005
Zotano, J. G. (2005) · Cuadernos Geográficos · doi:10.30827/cuadgeo.v37i2.1671 · Cited by 286
Gerard, K., Donaldson, C., & Maynard, A. (1989) · Diabetic Medicine · doi:10.1111/j.1464-5491.1989.tb02107.x · Cited by 145
Twenty-five years of essential medicines.
Quick, J. D., Hogerzeil, H. V., Velásquez, G., et al. (2002) · PubMed · doi:10.1590/s0042-96862002001100014 · Cited by 136
Polypill holds promise for people with chronic disease.
Wise, J. (2005) · Europe PMC (PubMed Central) · Cited by 28
Cited by
Global Surgery 2030: evidence and solutions for achieving health, welfare, and economic development
Meara, J. G., Leather, A. J. M., Hagander, L., Alkire, B. C., Alonso, N., Ameh, E. A., Bickler, S. W., Conteh, L., Dare, A. J., Davies, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60160-x · Cited by 3,851
Pharmaceutical pollution of the world’s rivers
Wilkinson, J. L., Boxall, A. B. A., Kolpin, D. W., Leung, K. M. Y., Lai, R. W. S., Galbán-Malagón, C., Adell, A. D., Mondon, J., Metian, M., Marchant, R. A., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113947119 · Cited by 1,633
Poverty and Access to Health Care in Developing Countries
Peters, D. H., Garg, A., Bloom, G., Walker, D. G., Brieger, W. R., & Hafizur Rahman, M. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1425.011 · Cited by 1,522
Oparil, S., Acelajado, M. C., Bakris, G. L., Berlowitz, D. R., Cífková, R., Dominiczak, A. F., Grassi, G., Jordan, J., Poulter, N. R., Rodgers, A., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.14 · Cited by 1,167
Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences
Chowdhury, R., Khan, H., Heydon, E., Shroufi, A., Fahimi, S., Moore, C., Stricker, B., Mendis, S., Hofman, A., Mant, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht295 · Cited by 931
Self-citation
Metadata
- Authors
- Mendis, S.
- Venue
- Bulletin of the World Health Organization
- Publisher
- WHO Press
- Published
- 2007-04-01
- Volume
- 85
- Issue
- 4
- Pages
- 279-288
- ISSN
- 0042-9686 (ISSN-L)
- OpenAlex
- W2086015900
- Cited by
- 487
- References
- 15
- FWCI
- 53.35
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.